Management of Osteoporosis in Postmenopausal Breast Cancer Survivors

Xuezhi Jiang, Department of ObGyn, The Reading Hospital, Reading, PA, United States; Department of ObGyn, Sidney Kimmel Medical College of Thomas Jefferson University, United States
Peter Schnatz, Reading Hospital
Risa Kagan, Sutter Health

Jiang X., Schnatz P.F., Kagan R. (2017) Management of Osteoporosis in Postmenopausal Breast Cancer Survivors. In: Pal L., Sayegh R. (eds) Essentials of Menopause Management. Springer, Cham

Print ISBN 978-3-319-42449-1
Online ISBN 978-3-319-42451-4


A 55-year-old Caucasian postmenopausal woman with BMI of 22.5 kg/m2 presents to the clinic for follow-up to discuss the results of her recent dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) scan. She has a personal history of premenopausal early-stage hormone receptor-positive breast cancer at age 47 and a family history of parental hip fracture. Following her initial breast cancer treatment, she received tamoxifen for 5 years (Age 47–52) followed by anastrozole (an aromatase inhibitor) until the current time. The DXA scan reports T-scores of −1.8 at the total hip and −1.6 at the lumbar spine. What would be your preferred management?